Israel Becomes the First Country Ever to Ban Fur

Israel Becomes the First Country Ever to Ban Fur

More proof that PETA could bring about the end of the fur industry: After years of persistent campaigning by the organization and local activists, Israel has banned the sale of fur, making it the first country in the world to do so.

The historic ban represents a victory for so many. PETA Senior Vice President of Campaigns Dan Mathews and PETA Honorary Director Pamela Anderson personally lobbied government officials in Tel Aviv and appealed to Prime Minister Benjamin Netanyahu to support a ban on fur. Local activists have campaigned for years to achieve such a ban. Israel Minister of Environmental Protection Gila Gamliel signed the bill into law today after an overwhelming 86% of Israelis showed support for the proposal. Most importantly, this victory belongs to animals—the rabbits, minks, foxes, and other vulnerable species who suffer and are killed for human vanity.

Pamela Anderson has been speaking out against the fur industry for years—the PETA honorary director was among the first to bare all for PETA’s “I’d Rather Go Naked Than Wear Fur” campaign.

I'd Rather Go Naked Than Wear Fur

For decades, PETA and our international affiliates have exposed horrific cruelty on fur farms, demonstrating that animals spend their entire lives confined to cramped, filthy wire cages. Fur farmers use the cheapest killing methods available, including neck-breaking, suffocation, poisoning, and genital electrocution. Numerous video investigations have revealed minks being gassed en masse, foxes being electrocuted, rabbits screaming in pain as they’re shocked with electrical devices, and numerous animals being skinned alive.

There’s another reason every country should follow in Israel’s footsteps: Cramming sick and stressed animals together in unsanitary conditions on fur farms creates the perfect breeding ground for deadly diseases. The novel coronavirus has been found on mink fur farms in a dozen countries—Canada, Denmark (where a variant of the disease in minks infected humans), France, Greece, Italy, Latvia, Lithuania, the Netherlands, Poland, Spain, Sweden, and the U.S.—resulting in the emergency mass slaughter of tens of millions of animals.

The momentum against fur continues to grow around the world.

Israel is in good company: California banned the sale of new fur statewide in 2019, and numerous top designers and retailers—including Macy’sNordstrom, Burberry, GucciVersaceMichael Kors, Jimmy Choo, and Giorgio Armani—have banned fur. Humane options—such as faux fur made from hemp, frayed denim, and even recycled plastic bottles—continue to advance and are in higher demand than ever before.

Join PETA in Urging Others to Ban Fur, Too

Israel—an entire country—has banned fur. Meanwhile, Canada Goose is still selling fur from loyal, sensitive coyotes caught in painful steel traps before being shot, bludgeoned, or killed in some other violent way. Click below to urge the retailer to ditch fur now!

Is my golf club membership a tax write off?

Is my golf club membership a tax write off?

Christopher J. Fitzsimmons CPA: That’s a good question. Unfortunately, golf club dues are never deductible. However, you may be able to deduct the cost of entertaining clients at your golf club. Only union dues or dues paid to professional organizations and Chambers of Commerce (if work related) are deductible. They fall into a group called ‘miscellaneous itemized deductions,’ which are limited so you won’t get a full deduction. Caution – these deductions have been eliminated effective 1/1/18.
Christopher J. Fitzsimmons CPA, P.C.
(914) 437-8600
3691 Old Yorktown Rd Suite 204,
Shrub Oak, New York 10588-1536
https://fitz-tax.com

Roberts & Ryan Welcomes Daniel Rice, Veteran US Army Officer

Roberts & Ryan Welcomes Daniel Rice, Veteran US Army Officer

NEW YORK, April 23, 2020 (Newswire.com) -​​​Roberts & Ryan Investments, Inc., one of America’s first Service-Disabled Veteran-Owned (SDVO) FINRA-registered broker-dealer, is pleased to announce that Daniel Rice, veteran U.S. Army officer, has joined the firm’s advisory board. Rice will assist Roberts & Ryan in expanding the firm’s offerings and engagements to corporations and institutional investors committed to enhancing opportunities and economic independence to veterans, disabled veterans, and their families.

Rice is President and one of the co-founders of Thayer Leadership Development Group (TLDG) at West Point. TLDG is one of the Top 40 ranked executive leader development companies globally as classified by Training Industry. TLDG works with Fortune 1000 companies to help build leaders of character using a proprietary method of developing leaders based on military leadership principles. In 10 years, TLDG has trained over 100,000 executives.

Under his vision and leadership, TLDG partnered with the Chief Executive magazine to create the Patriots in Business Awards to recognize corporations that go above and beyond to support our military, veterans and their families.

Rice is the publisher and co-author of the award-winning book “West Point Leadership: Profiles of Courage” and has been published several times in The Wall Street Journal, Chief Executive Magazine and Small Wars Journal. He has appeared on CNN, TODAY SHOW, FOX & FRIENDS, Bloomberg, MSNBC, NBC and other networks speaking on various national security and veterans’ issues.

“Dan is a tremendous addition to our team with his character, energy and his extensive corporate and financial network,” said Brian Rathjen, President of Roberts & Ryan Investments, Inc. “Dan is known nationally as a tireless supporter of U.S. national security and veteran issues, having served three times in the Army, recipient of the Purple Heart, and having helped educate thousands of American executives on the lessons that corporate leaders can learn from the military through his writings, speeches and advocacy.”

Dan is a graduate of West Point with a B.S. in National Security, holds an MBA from the Kellogg Graduate School of Business at Northwestern University and an M.S. in Marketing from Medill Graduate School at Northwestern University, and will receive an M.S.Ed. in Learning from the University of Pennsylvania in May 2020. He is also a doctoral candidate in the University of Pennsylvania Chief Learning Officer program.

In 2004, he volunteered to rejoin the Army after over a decade out of uniform and deployed to Iraq as an infantry officer based in Tikrit for over a year. In 2008, he served on the congressionally funded “Project for National Security Reform.” He has been awarded the Purple Heart, Ranger Tab, Combat Action Badge, Airborne Badge and other awards.

“It’s an honor to serve on the Roberts & Ryan team. Brian Rathjen has built a team of professional traders, many veterans themselves, each with considerable experience and expertise in their respective fields,” said Rice. “However, I’m most impressed with the incredible philanthropic support that Roberts & Ryan provide to veteran philanthropies that is unmatched by any other firm. I look forward to helping grow the firm and increasing philanthropic giving exponentially.”

Daniel Hodge, Founder of DCH Property Group, Aims to Build a £10M Real Estate Empire by Age 30

Daniel Hodge, Founder of DCH Property Group, Aims to Build a £10M Real Estate Empire by Age 30

Daniel Hodge, Founder of DCH Property Group, Aims to Build a £10M Real Estate Empire by Age 30

Daniel Hodge, founder, DCH Property Group

LONDON, May 5, 2020 (Newswire.com) – Daniel Hodge doesn’t believe in limits. He believes in setting the bar, clearing the bar, then raising it again. And to see his resume, one would have a hard time grasping that the man with the long list of accomplishments to his name is just 28. Most recently, Hodge is the founder of DCH Property Group, a London-based company that invests in undervalued properties throughout England and brings them back to market value.

Founded last year, DCH Property Group focuses on rehabbing distressed buildings in locations where the team’s research shows there is growth potential based on economic and demographic trends. In a nutshell, the company buys the properties, fixes them and rents them. According to Hodge, his company is able to readily identify an asset that fits its investment criteria, move swiftly to secure the deal then put its contractors to work to ensure the job is completed to the highest standards.

“In a short amount of time, we have developed trusted relationships within the UK real estate market that allowed us to identify, analyze, negotiate and finalize deals in every major city,” said Hodge. “We’ve earned a reputation for swift, top-quality execution and the communities in which we invest appreciate that.”

Since 2019, DCH has grown its portfolio to about £1.6m in assets under management and a 23 percent average return on investment with plans to grow that to £10m in assets under management, over the next two years – or by the time Hodge is just 30.

But just where does a 20-something entrepreneur get the dollars needed to invest in such properties? From the profits earned through his multi-million-dollar e-commerce jewelry brand, that’s where. The one he started when he was 25.

“I’ve always found e-commerce interesting and have been very fortunate with that company, but real estate is what really excites me. I have really honed in on real estate since last year as that’s always been my long-term goal. There has been a small set-back with COVID-19, but unexpected hurdles like these are all part of the journey,” said Hodge.

And that is where Hodge’s next career goal comes into play. He has set his sights on launching a UK-based property fund in his early 30s, just a few years away.

“I’ve witnessed firsthand how DCH’s projects have improved the quality of life in the places where we have purchased properties. I believe that my long-term legacy will be in helping build stronger and happier communities through the energy, passion and know-how I have in the real estate world. A property fund is the next natural step once I’ve hit a £10M portfolio,” he added.

Intralytix Receives Multimillion-Dollar Clinical Trial Award From NIAID to Manage Shigella Infections in Humans

Intralytix Receives Multimillion-Dollar Clinical Trial Award From NIAID to Manage Shigella Infections in Humans

Dr. Alexander Sulakvelidze

COLUMBIA, Md., May 4, 2020 (Newswire.com) –Intralytix, Inc. announced today that it has received a multimillion-dollar grant (AI 148054) from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), for the clinical development of its bacteriophage therapy preparation for managing infections caused by the bacterial pathogen Shigella. Dr. Alexander Sulakvelidze, Executive Vice President of Intralytix and the Program Director of the multi-PI grant, commented, “We are very pleased to have this collaborative opportunity with NIAID. The project will address a significant public health issue, as it is expected to help reduce the burden of disease caused by Shigella. It will also help enhance our program on developing bacteriophage-based therapeutic preparations as complementing modalities to other anti-infectives, such as vaccines and antibiotics, for managing bacterial diseases, including those caused by multi-drug resistant bacterial pathogens.” Dr. Sulakvelidze concluded, “This award paves the way for an important clinical study, and also shows that Intralytix continues to demonstrate innovative leadership in successfully developing bacteriophage products for various applications.”

This NIAID-funded project will assess the safety and efficacy of the Shigella bacteriophage preparation developed by Intralytix in Phase 1/2a clinical trials. “We believe that our bacteriophage preparation will help reduce the severity or incidence of disease caused by Shigella,” commented Dr. Jennifer Schwartz, Director of Clinical Development at Intralytix. She noted that “Shigella infections affect approximately 125 million people worldwide each year, with the majority of the 14,000 associated deaths occurring in young children. Bacteriophage therapy has been and is used in Eastern Europe and Asia but has not been approved by the U.S. Food and Drug Administration due to the lack of adequate clinical trials. Not only are these Phase 1/2a trials expected to have a public health impact on Shigella infections, but they will also help pave the way for the development of bacteriophage therapies against other important bacterial pathogens, including those having epidemic potential, such as cholera. We look forward to starting this important project in collaboration with the NIAID and our academic collaborators.”